Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 6/20 | 0.56 |
| ▸ | MDM4 | O15151 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | TLR2 | O60603 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | CASP3 | P42574 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL800090 | 0.94 | MDM4 (0.56) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL119475 | 0.94 | MDM4 (0.56) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL29908079 | 0.94 | MDM4 (0.56) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL29401101 | 0.94 | MDM4 (0.56) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL5182292 | 0.94 | MDM4 (0.56) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL29352431 | 0.94 | MDM4 (0.56) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL29682425 | 0.94 | MDM4 (0.56) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL30749111 | 0.92 | KMT2A (0.62) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL19951678 | 0.92 | KMT2A (0.62) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL30819573 | 0.92 | KMT2A (0.62) | MDM2MDM4TP53TLR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-04 | — | — | US | disclosed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | VIP, QPCT, PTMS | MDM2 3406/4885MDM4 2377/4885TP53 3358/4885 |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | MDM2 423/4885MDM4 1648/4885TP53 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.